These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12042846)

  • 41. Great company, bad stock.
    Jacobs T
    Nat Biotechnol; 2005 Feb; 23(2):173. PubMed ID: 15696142
    [No Abstract]   [Full Text] [Related]  

  • 42. No pain, no gain?
    Jacobs T
    Nat Biotechnol; 2005 Aug; 23(8):934. PubMed ID: 16082357
    [No Abstract]   [Full Text] [Related]  

  • 43. Hidden in plain view.
    Jacobs T
    Nat Biotechnol; 2003 Jun; 21(6):603. PubMed ID: 12776141
    [No Abstract]   [Full Text] [Related]  

  • 44. Will investors return to biotechnology?
    Dorey E
    Nat Biotechnol; 1999 Feb; 17(2):128. PubMed ID: 10052340
    [No Abstract]   [Full Text] [Related]  

  • 45. Antivirals--an increasingly healthy investment.
    McCarthy B
    Nat Biotechnol; 2007 Dec; 25(12):1390-3. PubMed ID: 18066033
    [No Abstract]   [Full Text] [Related]  

  • 46. When your stock takes a nosedive.
    Jacobs T
    Nat Biotechnol; 2006 Feb; 24(2):144. PubMed ID: 16465152
    [No Abstract]   [Full Text] [Related]  

  • 47. A rollercoaster ride.
    Jacobs T
    Nat Biotechnol; 2006 Mar; 24(3):284. PubMed ID: 16525390
    [No Abstract]   [Full Text] [Related]  

  • 48. Sumitomo buys Oxford finance.
    Bouchie A
    Nat Biotechnol; 2004 Apr; 22(4):480. PubMed ID: 15085808
    [No Abstract]   [Full Text] [Related]  

  • 49. Investors explore buying technology data.
    Morrissey J
    Mod Healthc; 1996 Jan; 26(3):19. PubMed ID: 10153971
    [No Abstract]   [Full Text] [Related]  

  • 50. Earlier stage biotechs attract partners.
    Ratner M
    Nat Biotechnol; 2005 May; 23(5):509. PubMed ID: 15877052
    [No Abstract]   [Full Text] [Related]  

  • 51. Sugen's strategy: a signal for P&U purchase.
    Glaser V
    Nat Biotechnol; 1999 Aug; 17(8):745-6. PubMed ID: 10429230
    [No Abstract]   [Full Text] [Related]  

  • 52. Rx for investors.
    Stires D
    Fortune; 2004 May; 149(9):158-60, 162, 164 passim. PubMed ID: 15124332
    [No Abstract]   [Full Text] [Related]  

  • 53. Western biotechs ponder follow-on possibilities.
    Waltz E
    Nat Biotechnol; 2008 Sep; 26(9):962-3. PubMed ID: 18779793
    [No Abstract]   [Full Text] [Related]  

  • 54. Antibiotics--an investment worth making?
    Christoffersen RE
    Nat Biotechnol; 2006 Dec; 24(12):1512-4. PubMed ID: 17160052
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The further evolution of biotech.
    Nagle T; Berg C; Nassr R; Pang K
    Nat Rev Drug Discov; 2003 Jan; 2(1):75-9. PubMed ID: 12509762
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New IGF drug stirs competition in growth factor segment.
    Ratner M
    Nat Biotechnol; 2005 Oct; 23(10):1192. PubMed ID: 16211044
    [No Abstract]   [Full Text] [Related]  

  • 57. Michigan's next wave of biopharmaceutical entrepreneurship.
    Kerppola R; van de Walle M; Surine S
    Nat Biotechnol; 2003 Sep; 21(9):1109-11. PubMed ID: 12949575
    [No Abstract]   [Full Text] [Related]  

  • 58. Value creation and sharing among universities, biotechnology and pharma.
    Edwards MG; Murray F; Yu R
    Nat Biotechnol; 2003 Jun; 21(6):618-24. PubMed ID: 12776145
    [No Abstract]   [Full Text] [Related]  

  • 59. What's fueling the biotech engine?
    Aggarwal S
    Nat Biotechnol; 2007 Oct; 25(10):1097-104. PubMed ID: 17921989
    [No Abstract]   [Full Text] [Related]  

  • 60. Biotech R&D still reeling.
    Lawrence S
    Nat Biotechnol; 2004 Sep; 22(9):1068. PubMed ID: 15340460
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.